The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
@HighWireTalk
Thank you National Pulse for reporting on @ICAN's blockbuster news about Fauci, Dazsak & the Wuhan lab RT UNREDACTED: Fauci Emails Show EcoHealth's Daszak Admitting Collaboration With CCP Virologists. https://twitter.com/HighWireTalk/status/1427314680800976900
@ydeigin
Even China’s “useful fool” Western virologist Embarek which Chief Conspirator Peter Daszak has lobbied for installing as the head of the WHO joke of Wuhan inquiry is now backpedaling.
Your house of cards is collapsing, Fauci and Dazsak. Reckoning is near. https://twitter.com/ydeigin/status/1425767812358881281
@ianbirrell
Wow! Patient Zero in the pandemic may have been infected in a laboratory says @WHO
inquiry chief Peter Ben Embarek https://twitter.com/ianbirrell/status/1425757674264801282
https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine
inhaled AZ vax as a booster for people who had the 2 shots
A Phase I Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers (COVAXAER01)
https://clinicaltrials.gov/ct2/show/NCT05007275
@PrisonMatrix
Covid Pass, sent from Italy!
8 SHOTS!!!!!!
https://twitter.com/PrisonMatrix/status/1428562209081335808/photo/1
AZD7442, a combination of two LONG-ACTING Antibodies (LAAB),
AZN got the monoclonal antibodies from Vanderbilt university &
engineered them with the company's proprietary YTE half-life extension technology
BARDA and DoD (as a part of Warp Speed ) gave $486 million to AstraZeneca ( AZD7442 ) p3, to develop long-acting monoclonal antibodies with 100000 pre-order
wonder if sng001 can be made Long-Acting
cross ramp:
if interested in
Long-acting mAb ( LAAB )
Long-acting Injectables ( LAI )
DIPG
have a look at
https://www.midatechpharma.com/media/pages/investors/presentations-and-webcasts/98d47e6c68-1626951755/21.06.19-mtph-corporate-overview-june-2021.pdf
" IFITM proteins promote SARS-CoV-2 infection of human lung cells "
Posted August 18, 2020
https://www.biorxiv.org/content/10.1101/2020.08.18.255935v1
> IFITMs enhance SARS-CoV-2 infection in primary human lung cells <
" Taken together, our results show that endogenous expression of IFITM proteins promotes SARS-CoV-2 replication in primary human lung cells, especially in the presence of IFN-Ăź. "
https://www.nature.com/articles/s41467-021-24817-y
Translated from German by
@PZ_Nachrichten
Certain interferon-induced #Proteine in the body are usually known for their antiviral effects. at #Covid19 it is obviously different.#SARSCoV2 turns the tables and uses these proteins to become even more infectious
https://twitter.com/PZ_Nachrichten/status/1423218294929203201
Google translation from German
" So-called interferon-induced transmembrane proteins (IFITM) had a good reputation so far, as they can keep various viral pathogens, such as HI or influenza viruses, at bay.
A team led by Caterina Prelli Bozzo from the University of Ulm is now reporting on a negative characteristic of IFITM in the specialist magazine "Nature Communications".
A study shows that SARS-CoV-2 can use IFITM for the effective infection of human cells.
“We were very surprised by these results. Until now, interferon-induced transmembrane proteins were better known for their antiviral effects, ”says senior author Professor Dr. Frank Kirchhoff, also from Ulm, in a press release from the university. "
https://www.pharmazeutische-zeitung.de/coronavirus-macht-aus-gegnern-helfer-127275/
" Interferon-induced transmembrane proteins (IFITMs 1, 2 and 3) can restrict viral pathogens,
but pro- and anti-viral activities have been reported for coronaviruses.
Here, we show that artificial overexpression of IFITMs blocks SARS-CoV-2 infection.
However, endogenous IFITM expression supports efficient infection of SARS-CoV-2 in human lung cells "
https://www.nature.com/articles/s41467-021-24817-y
@AlionderCPC
ILC1s demonstrate memory responses and contribute to trained immunity.
Increased numbers of circulating ILC1s correlates with disease severity and exacerbation in many chronic diseases like in the lung during #COPD pathogenesis
https://twitter.com/AlionderCPC/status/1421044468032102401
" The lung epithelium and also liver hepatocytes are targets of SARS-CoV-2 infection and overshooting immune responses can trigger both severe lung and liver damage. ILC1s may contribute to the early defense against viral infection but also to the pathogenesis of immunemediated tissue damage. In combination with systemic in?ammation as a fuel for liver injury in COVID-19 patients, local autoenhancement of ILC1 generation and cytokine expression may contribute to both liver and lung damage. "
Thomas M. Conlon, Percy A. Knolle and Ali Ă–nder Yildirim
Published 29 July 2021
https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
"Everyone with severe COVID-19 had a blunted interferon response early on in their epithelial cells and were never able to ramp up a defense." Says @ordovas_phd
https://www.biotechniques.com/covid-19/sniffing-out-the-source-influencing-covid-19-severity/
" 20 more vaccinations to go "
https://twitter.com/favourafolabi/status/1420864201191477248
p4
Increasing percentage of vaccinated persons among those hospitalized in COVID-NET
https://context-cdn.washingtonpost.com/notes/prod/default/documents/54f57708-a529-4a33-9a44-b66d719070d9/note/753667d6-8c61-495f-b669-5308f2827155.#page=1
Items reviewed by the DSMB include:
* Interim/cumulative data for evidence of study-related adverse events;
* Interim/cumulative data for evidence of efficacy according to pre-established statistical guidelines, if appropriate;
* Data quality, completeness, and timeliness;
* Performance of individual centers;
* Adequacy of compliance with goals for recruitment and retention, including those related to the participation of women and minorities;
* Adherence to the protocol;
* Factors that might affect the study outcome or compromise the confidentiality of the trial data (such as protocol violations, unmasking, etc.); and,
* Factors external to the study such as scientific or therapeutic developments that may impact participant safety or the ethics of the study.
https://www.nidcr.nih.gov/research/human-subjects-research/toolkit-and-education-materials/interventional-studies/data-and-safety-monitoring-board-guidelines
https://www.ctti-clinicaltrials.org/files/recommendations/dmc-recommendations.pdf
some copies still there
https://thedailydan.tumblr.com/post/657994405473632256/yesterday-nbc-news-correspondent-ken-dilanian
" It has been found that about 3.5% of COVID-19 patients had known
autosomal-recessive (AR) deficiencies [interferon regulatory factor 7 (IRF7) and IFNAR1] and
autosomal-dominant deficiencies (AD) [toll-like receptor 3 (TLR3), UNC93B1, TICAM1, TBK1, IRF3, IRF7, IFNAR1, and IFNAR2]. These findings suggested important roles of not only IRF3 or IRF7 but also TLR3 in the control of SARS-CoV-2 infection "
Farooq Rashid1, Muhammad Suleman, Abdullah Shah, Emmanuel Enoch Dzakah, Haiying Wang, Shuyi Chen and
Shixing Tang
16 July 2021
good read here with visual
https://www.nature.com/articles/d41586-021-02039-y
" And this June, researchers reported mutations in the Alpha variant that seem to enable it to subdue interferon production even more efficiently "
" a study reported that the Delta variant grew more rapidly and at higher levels inside people’s lungs and throats than did earlier versions of the virus "
28 July 2021
Megan Scudellari
30 month contract for ÂŁ3.185 billion being tendered by Govt to sort blood clots.
https://www.contractsfinder.service.gov.uk/notice/bbec3a9a-168a-46c5-a71d-990c2a8a8212?origin=SearchResults&p=1